Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein

Microbes and Infection

Volumn 8, Issue 4, 2006, Pages 1090-1097

  Hu, Rongliang ^a   Zhang, Shoufeng ^a   Fooks, Anthony R ^b   Yuan, Huijun ^a   Liu, Ye ^a   Li, Haitao ^a   Tu, Changchun ^a   Xia, Xianzhu ^a   Xiao, Yueqiang ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b VETERINARY LABORATORIES AGENCY   (United Kingdom)

Author keywords

Canine adenovirus type 2; Dogs; Immunization; Rabies; Rabies virus glycoprotein; Recombinant vaccine

Indexed keywords

CANINE ADENOVIRUS TYPE 2 VACCINE; COMPLEMENTARY DNA; KENNEL COUGH VACCINE; NEUTRALIZING ANTIBODY; RABIES VACCINE; RECOMBINANT DNA; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ADENOVIRUS 2; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DOG; IMMUNE RESPONSE; IMMUNIZATION; INOCULATION; KIDNEY CELL CULTURE; LD 50; LETHALITY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RABIES; RABIES VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRUSES, CANINE; ANIMALS; ANTIBODIES, VIRAL; DOGS; DRUG EVALUATION, PRECLINICAL; GENETIC VECTORS; GLYCOPROTEINS; IMMUNIZATION SCHEDULE; INJECTIONS, SUBCUTANEOUS; MICE; NEUTRALIZATION TESTS; RABIES; RABIES VACCINES; RABIES VIRUS; REASSORTANT VIRUSES; VACCINES, DNA; VIRAL PROTEINS;

ANIMALIA; CANINE ADENOVIRUS TYPE 2; CANIS FAMILIARIS; CHICKEN ANEMIA VIRUS; HUMAN ADENOVIRUS TYPE 2; RABIES VIRUS;

EID: 33646146708     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2005.11.007     Document Type: Article

References (39)

1. World Health Organization Media Center, Rabies Fact Sheet, 2001, N°99.
2. Zhang Y.Z., Xia D.L., Sun Y.H., Yang X.R., and Yan Y.Z. The epidemic situation of human rabies from 1984-2002 and its preventive measures in China. Chinese J. Epidem. 24 10 (2003) 883-888
3. Rupprecht C.E., Hanlon C.A., Blanton J., Manangan J., Morrill P., Murphy S., Niezgoda M., Orciari L.A., Schumacher C.L., and Dietzschold B. Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res. 111 1 (2005) 101-105
4. WHO Expert Committee on rabies. WHO Technical report Series 824 (Eighth report) (1992), World health organization, Geneva pp. 2-32
5. Bellinger D.A., Chang J., Bunn T.O., Pick J.R., Murphy M., and Rahija R. Rabies induced in a cat by high-egg-passage Flury strain vaccine. J. Am. Vet. Med. Assoc. 183 (1983) 997-998
6. Okolo M.I. Vaccine-induced rabies infection in rural dogs in Anambra State, Nigeria. Microbios 57 (1989) 105-112
7. Charlton K.M., Artois M., Prevec L., Campbell J.B., Casey G.A., Wandeler A.I., and Armstrong J. Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Arch. Virol. 123 1-2 (1992) 169-179
8. Prevec L., Campbell J.B., Christie B.S., Belbeck L., and Graham F.L. A recombinant human adenovirus vaccine against rabies. J. Infect. Dis. 161 1 (1990) 27-30
9. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 286 5448 (1999) 2244-2245
10. Meyerholz D.K., Grubor B., Gallup J.M., Lehmkuhl H.D., Anderson R.D., Lazic T., and Ackermann M.R. Adenovirus-mediated gene therapy enhances parainfluenza virus 3 infection in neonatal lambs. J. Clin. Microbiol. 42 10 (2004) 4780-4787
11. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., Wilson J.M., and Batshaw M.L. Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Hum. Gene. Ther. 13 5 (2002) 579-604
12. Brochier B., Kieny M.P., Costy F., Coppens P., Bauduin B., Lecocq J.P., Languet B., Chappuis G., Desmettre P., Afiademanyo K., Libois R., and Pastoret P.P. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 354 (1991) 520-522
13. Wiktor T.J., Macfalan R.I., Reagan K.J., Dietzschold B., Curtis P.J., Wunner W.H., Kieny M.P., Lathe R., Lecocq J.P., Mackett M., Moss B., and Koprowski H. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 7194-7198
14. Rupprecht C.E., Blass L., Smith K., Orciari L.A., Niezgoda M., Whitfield S.G., Gibbons R.V., Guerra M., and Hanlon C.A. Human infection due to recombinant vaccinia-rabies glycoprotein virus. New Eng. J. Med. 345 8 (2001) 582-586
15. Fischer L., Tronel J.P., Pardo-David C., Tanner P., Colombet G., Minke J., and Audonnet J.C. Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge. Vaccine 20 (2002) 3485-3497
16. Zhang S.F., Hu R.L., Niu J.Q., and Xia X.Z. Cloning and identification of the full length infectious genome of canine adenovirus type-2. Chinese J. Vet. Med 22 5 (2002) 533-535
17. Meslin F.-X., Kaplan M.M., and Koprowski H. Laboratory Techniques in Rabies. Fourth ed. (1996), World Health Organization, Geneva pp. 80-86
18. Rosenbaum M.J., Edwards E.A., and Sullivan E.J. Micromethods for respiratory virus seroepidemiology. Health. Lab. Sci. 7 (1970) 42-53
19. Sambrook J., Fritsch E.F., and Maniatis T. Molecular Cloning: A Laboratory Manual. second ed. (1989), Cold Spring Harbor Laboratory Press, New York pp. 1.21-6.60
20. Burnette W.N. Western blotting: electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 112 2 (1981) 195-203
21. Yin Z., and Liu J.H. Animal Virology (1997), Chinese Science Press, Beijing pp. 323-363
22. Schmidt N.J., Lennette E.H., and King C.J. Neutralizing, hemagglutination-inhibiting and group complement-fixing antibody responses in human adenovirus infection. J. Immun. 97 1 (1996) 64-74
23. Cliquet F., Aubert M., and Sagne L. Development of a fluorescent antibody virus neutralization test (FAVN test) for the quantitation of rabies-neutralising antibody. J. Immunol. Methods 212 1 (1998) 79-87
24. Gamoh K., Senda M., Itoh O., Muramatsu M., Hirayama N., Koike R., Endoh Y.S., and Minamoto N. Use of ELISA for in vitro potency test of rabies vaccines for animal use. Biologicals 24 2 (1996) 95-101
25. Whitby J.E., Heaton P.R., Whitby H.E., O'Sullivan E., and Johnstone P. Rapid detection of rabies and rabies-related viruses by RT-PCR and enzyme-linked immunosorbent assay. J. Virol. Methods 69 1-2 (1997) 63-72
26. Wilkinson J.W., and Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res. 20 9 (1992) 2233-2239
27. Baer G.M., Brooks R.C., and Foggin C.M. Oral vaccination of dogs fed canine adenovirus in baits. Am. J. Vet. Res. 50 6 (1989) 836-837
28. Edinboro C.H., Ward M.P., and Glickman L.T. A placebo-controlled trial of two intranasal vaccines to prevent tracheobronchitis (kennel cough) in dogs entering a humane shelter. Prev. Vet. Med 62 2 (2004) 89-99
29. Sumner J.W., Shaddock J.H., Wu G.J., and Baer G.M. Oral administration of an attenuated strain of canine adenovirus (type 2) to raccoons, foxes, skunk, and mongoose. Am. J. Vet. Res. 49 2 (1988) 169-171
30. Tuboly T., and Nagy E. Construction and characterization of recombinant porcine adenovirus serotype 5 expressing the transmissible gastroenteritis virus spike gene. J. Gen. Virol. 82 1 (2001) 183-190
31. Zarnke R.L., and Evans M.B. Serologic survey for infectious canine hepatitis virus in grizzly bears (Ursus arctos) from Alaska, 1973 to 1987. J. Wildl. Dis. 25 4 (1989) 568-573
32. Bass E.P., Gill M.A., and Beckenhauer W.H. Evaluation of a canine adenovirus type 2 strain as a replacement for infectious canine hepatitis vaccine. J. Am. Vet. Med. Assoc. 177 3 (1980) 234-242
33. Kremer E.J. CAR chasing: canine adenovirus vectors-all bite and no bark?. J. Gene. Med. 6 Suppl. 1 (2004) S139-S151
34. Zakhartchouk A.N., Reddy P.S., Baxi M., Baca-Estrada M.E., Mehtali M., Babiuk L.A., and Tikoo S.K. Construction and characterization of E3-deleted bovine adenovirus type 3 expressing full-length and truncated form of bovine herpesvirus type 1 glycoprotein gD. Virology 250 1 (1998) 220-229
35. Wold W.S., and Gooding L.R. Region E3 of adenovirus: a cassette of genes involved in host immuno-surveillance and virus-cell interactions. Virology 184 (1991) 1-8
36. Ginsberg H.S., Lundholm-Beauchamp U., Horswood R.L., Pernis B., Wold W.S., Chanock R.M., and Prince G.A. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 3823-3827
37. Xiang Z.Q., Yang Y., Wilson J.M., and Ertl H.C. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219 (1996) 220-227
38. Perrin P., Jacob Y., Aguilar-Setien A., Loza-Rubio E., Jallet C., Desmezieres E., Aubert M., Cliquet E., and Tordo N. Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 18 (2000) 479-486
39. Lodmell D.L., Parnell M.J., Bailey J.R., Ewalt L.C., and Hanlon C.A. One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine 20 (2001) 838-844